Oryzon Reports Dosing of the First Patient with Iadademstat + Venetoclax + Azacitidine in P-I Trial to Treat 1L Acute Myeloid Leukemia (AML)
Shots:
- The first patient was dosed with iadademstat (ORY-1001) + venetoclax + azacitidine combination to treat AML naïve patients (n=45) under the P-I trial to evaluate the safety, tolerability, preliminary efficacy & optimal dose. Trial will be managed & funded by NCI under CRADA
- In addition, the combination is being evaluated to treat 1L AML in an IIT P-I trial at OHSU Knight Cancer Institute, plus iadademstat is also being assessed with gilteritinib in a company-funded P-Ib trial to treat r/r FLT3mut+ AML
- Iadademstat (oral small molecule) inhibits the interaction of LSD1 enzyme with GFI-1 transcription factor to prevent disease progression in leukemia
Ref: GlobeNewswire | Image: Oryzon
Related News:- Bayer Reports the US FDA’s sNDA Acceptance of Nubeqa (Darolutamide) to Treat Metastatic Hormone-Sensitive Prostate Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
